Highlights Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
5.56 ^USD	-6.40%		-7.18%	-13.80%

May. 06	Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	Mar. 05	CI
Eli Lilly: Foghorn's anti-tumor drug selected for clinical development	Feb. 08	CF
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	Feb. 08	DJ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	Feb. 08	CI
Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	Jan. 08	CI
Foghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference	23-10-04	CI
Foghorn Therapeutics Inc. Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed And/Or Refractory AML	23-08-31	CI
Foghorn Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Foghorn Therapeutics Announces FDA Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients	23-06-05	CI
FOGHORN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-08	AQ
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Foghorn Therapeutics pauses enrollment in cancer drug study	23-04-24	RE
Foghorn Therapeutics Inc. Provides an Update on FHD-609	23-04-24	CI
Foghorn Therapeutics Inc. to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286 At the 2023 American Association for Cancer Research Annual Meeting	23-04-10	CI
FOGHORN THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-09	AQ
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Foghorn Therapeutics Fiscal 2022 Loss Narrows as Revenue Increases	23-03-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Highlights

Filters